Genetic and immune factors underlying the efficacy of cetuximab and panitumumab in the treatment of patients with metastatic colorectal cancer

Efficacy of monoclonal anti-EGFR antibodies (cetuximab, panitumumab) used in combination with chemotherapy or alone has been demonstrated in clinical trials of patients with mCRC. Both drugs block signaling EGFR pathway in malignant cells (blocking ligand binding and EGFR dimerization). Obtaining tr...

Descripción completa

Detalles Bibliográficos
Autores principales: Krawczyk, Paweł Adam, Kowalski, Dariusz M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Termedia Publishing House 2013
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4037996/
https://www.ncbi.nlm.nih.gov/pubmed/24876815
http://dx.doi.org/10.5114/wo.2013.38566

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4037996/
https://www.ncbi.nlm.nih.gov/pubmed/24876815
http://dx.doi.org/10.5114/wo.2013.38566

Ejemplares similares